ESMO 2008 - GSK To Present Encouraging New Data Supporting Late Stage Development Programme

At the 33rd meeting of the European Society for Medical Oncology (ESMO) Stockholm, Sweden, GlaxoSmithKline (GSK) Oncology will present exciting new data for Tyverb® (lapatinib) and pazopanib. These new data form the foundation of Phase III development plans for these molecules across a variety of tumours including Head and Neck, Ovarian, Lung, and Soft Tissue Sarcoma.